

## **Supporting Information**

### **Magnetite-Quantum Dot Immunoarray for Plasmon-coupled-Fluorescence Imaging of Blood Insulin and Glycated Hemoglobin**

Vini Singh<sup>a</sup>, Rajasekhara Nerimetla<sup>a</sup>, Ming Yang<sup>b</sup>, and Sadagopan Krishnan<sup>a,\*</sup>

<sup>a</sup> Department of Chemistry, Oklahoma State University, Stillwater, OK 74078, USA

<sup>b</sup> Department of Plant Biology, Ecology, and Evolution, Oklahoma State University, Stillwater, OK 74078, USA

#### **Table of Contents:**

**Table S1.** DLS and zeta potential measurements of insulin and HbA1c conjugates.

**Table S2.** Different strategies for insulin and HbA1c detection in clinical matrices.

**Figure S1.** Negative SPR reflectivity upon binding of mixed thrombin and PDGF conjugates.

**Figure S2.** Standard curve of cyanmethemoglobin standards and UV-vis spectra of prepared HbA1c standards.

**Figure S3.** Simulated and experimental SPR sensograms of insulin and HbA1c.

**Figure S4.** Plot of  $k_{obs}$  and concentration of insulin and HbA1c.


**Table S1.** DLS and zeta potential measurements of insulin and HbA1c conjugates (mean  $\pm$  standard deviation, N = 3 replicates).

Sample	Hydrodynamic size (nm)	Zeta potential (mV)
MNP (amine functionalized)	115 $\pm$ 2	45 $\pm$ 7
1. MNP-QD <sub>800</sub>	143 $\pm$ 3	-24 $\pm$ 1
MNP-QD <sub>800</sub> -aptamer	186 $\pm$ 11	-10 $\pm$ 2
MNP-QD <sub>800</sub> -aptamer-control (unspiked with insulin)	480 $\pm$ 22	-11 $\pm$ 1
MNP-QD <sub>800</sub> -aptamer-spiked with 50 pM insulin	681 $\pm$ 22	-14 $\pm$ 1
2. MNP-QD <sub>565</sub>	127 $\pm$ 1	-22 $\pm$ 4
MNP-QD <sub>565</sub> -aptamer	223 $\pm$ 7	-9 $\pm$ 2
MNP-QD <sub>565</sub> -aptamer-control (unspiked with HbA1c)	674 $\pm$ 19	-10 $\pm$ 1
MNP-QD <sub>565</sub> -aptamer-spiked with 6% HbA1c	759 $\pm$ 25	-12 $\pm$ 1

**Table S2.** Different strategies for insulin and HbA1c detection in clinical matrices.


Strategies	Matrix	Limit of Detection (LOD)	Reference
<b><u>Insulin:</u></b> 1. ELISA from Merckodia Inc.	Serum or plasma	0.9 pM	-
2. Solid phase extraction liquid chromatography mass spectrometry (SPE-LCMS) quantitation of endogenous insulin levels	Whole blood hemolyzed to extract plasma; plasma diluted 1:1 with 50 mM acetic acid	Limit of quantitation (LOQ) was 172 pM	[1]
3. Bloodspot chemiluminescent insulin assay	Insulin standards prepared in 0.55 haematocrit	5.9 pM	[2]
4. Chemiluminescence bead based sandwich immunoassay	Plasma	0.3 pM	[3]
5. Gold coated crystal-antibody (Au-Ab <sub>insulin</sub> ) modified mass and impedimetric sensor	50% serum	5 pM	[4]
6. Nanotube-pyrene-Ab <sub>insulin</sub> voltammetric sensor	50% serum	5 pM	[5]
7. Au-Ab <sub>insulin</sub> modified SPRi sensor (sandwich assay)	50% serum	4 pM	[6]
8. MNP-QD-aptamer - insulin conjugation (sandwich assay with Au-dendrimer-Ab <sub>insulin</sub> modified surface)	Unprocessed whole blood diluted 20-times in PBS	4 pM	This study

<b>HbA1c:</b>			
9. Zirconium dioxide nanoparticles ferrocene boronic acid (ZrO <sub>2</sub> /FcBA) modified amperometric HbA1c biosensor	Real blood samples diluted with PBS to give 20 μM total hemoglobin concentration	HbA1c control samples of concentrations 6, 8, 10, and 14% were purchased	[7]
10. Thiophene-3-boronic acid (T3BA) self-assembled monolayer (SAM) covered Au impedimetric HbA1c sensor	HbA1c reference solutions were pretreated	HbA1c reference solutions of concentrations 4.54, 5.27, 6.96, 9.24, and 11.58% were purchased	[8]
11. Fluorinated polydimethyl siloxane (PDMS) modified antibody microarrays using enhanced chemiluminescent luminol reagent kit (ECL)	No sample pretreatment. Whole blood diluted 5 orders of magnitude	3.58 ng/mL of total hemoglobin and 0.20 ng/mL of HbA1c (5.6%)	[9]
12. Gold nanoparticle modified amino phenyl boronic acid modified ampero-metric HbA1c sensor	Lyophilized HbA1c in pretreated hemoglobin with 10-fold dilution	0.052%	[10]
13. Luminol chemiluminescence HbA1c biosensor	HbA1c in PBS buffer pH 8. Real blood samples diluted 50-fold	10 ng/mL (2.9%)	[11]
14. MNP-QD-aptamer-HbA1c conjugation (sandwich assay with Au-dendrimer-Ab <sub>HbA1c</sub> modified surface)	Unprocessed whole blood diluted 20-times in PBS	1%	This study



**Figure S1.** Negative SPR reflectivity upon binding of mixed thrombin and PDGF conjugates on surface immobilized (a) anti-insulin or (b) anti-HbA1c antibody.


Cyanmethemoglobin assay for quantitation of total hemoglobin in HbA1c standards.



**Figure S2.** (A) Standard curve of cyanmethemoglobin standards and (B) UV-vis spectra of prepared HbA1c standards.

The kinetic analysis was performed using the kinetic equations shown below.

The interaction between the two macromolecules follows a one-to-one binding reaction and is written as:



$$\text{Association phase: } \frac{d[AB]}{dt} = k_a[A][B] - k_d[AB] \quad (1)$$

$$\text{Dissociation phase: } \frac{d[AB]}{dt} = -k_d[AB] \quad (2)$$

where A is the antibody of insulin or HbA1c immobilized on the SPR chip, B is the concentration of insulin or HbA1c conjugated to the MNP-QD-aptamer, and AB is the complex formed between insulin (or HbA1c) and surface antibody. Because the concentration of A is constant, the complex formation has been considered to follow a pseudo first order kinetics.<sup>12-14</sup> The SPR response of the interaction with time can be written as:

$$\frac{dR}{dt} = k_a CR_{max} - (k_a C + k_d)R_t \quad (3)$$


The integrated form of (3) is,<sup>15</sup>

$$R_t = \frac{k_a CR_{max}[1 - e^{-(k_a C + k_d)t}]}{k_a C + k_d} + R_0 \quad (4)$$


$$k_{obs} = k_a C + k_d \quad (5)$$

$$K_D = \frac{k_d}{k_a} \quad (6)$$

where  $R_t$  is the SPR response at time  $t$ ,  $R_{\max}$  is the maximum reflectivity change,  $R_0$  is the SPR response at time  $t = 0$ ,  $C$  is the concentration of the analyte (insulin or HbA1c),  $k_a$  is the association rate constant,  $k_d$  is the dissociation rate constant, and  $K_D$  is the binding constant.



**Figure S3.** Simulated (red) and experimental SPR sensograms (black, data of Fig. 4A-B in main Ms.) of (A) insulin and (B) HbA1c.



**Figure S4.** Plot of  $k_{\text{obs}}$  and concentration of (A) insulin and (B) HbA1c.

## References.

- (1) Darby, S. M.; Miller, M. L.; Allen, R. O.; LeBeau, M. A. A mass spectrometric method for quantitation of intact insulin in blood samples. *J. Anal. Toxicol.* **2001**, *25*, 8-14.
- (2) Butter, N. L.; Hattersley, A. T.; Clark, P. M. Development of a bloodspot assay for insulin. *Clin. Chim. Acta* **2001**, *310*, 141-150.
- (3) Poulsen, F.; Jensen, K. B. A luminescent oxygen channeling immunoassay for the determination of insulin in human plasma. *J. Biomol. Screen.* **2007**, *12*, 240 – 247.
- (4) Singh, V.; Krishnan, S. An electrochemical mass sensor for diagnosing diabetes in human serum. *Analyst* **2014**, *139*, 724-728.
- (5) Singh, V.; Krishnan, S. Voltammetric immunosensor assembled on carbon-pyrenyl nanostructures for clinical diagnosis of type of diabetes. *Anal. Chem.* **2015**, *87*, 2648-2654.
- (6) Singh, V.; Rodenbaugh, C.; Krishnan, S. Magnetic optical microarray imager for diagnosing type of diabetes in clinical blood serum samples. *ACS Sens.* **2016**, *1*, 437-443.
- (7) Liu, S.; Wollenberger, U.; Katterle, M.; Scheller, F. W. Ferroceneboronic acid-based amperometric biosensor for glycosylated hemoglobin. *Sens. Actuator B Chem.* **2006**, *113*, 623-629.
- (8) Park, J. Y.; Chang, B. Y.; Nam, H.; Park, S. M. Selective electrochemical sensing of glycosylated hemoglobin (HbA1c) on thiophene-3-boronic acid self-assembled monolayer covered gold electrodes. *Anal. Chem.* **2008**, *80*, 8035-8044.
- (9) Chen, H. H.; Wu, C. H.; Tsai, M. L.; Huang, Y. J.; Chen, S. H. Detection of total and a1c-glycosylated hemoglobin in human whole blood using sandwich immunoassays on polydimethylsiloxane-based antibody microarrays. *Anal. Chem.* **2012**, *84*, 8635-8641.
- (10) Kim, D. –M.; Shim, Y. –B. Disposable amperometric glycosylated hemoglobin sensor for the finger prick blood test. *Anal. Chem.* **2013**, *85*, 6536-6543.
- (11) Ahn, K. S.; Lee, J. H.; Park, J. M.; Choi, H. N.; Lee, W. Y. Luminol chemiluminescence biosensor for glycosylated hemoglobin (HbA1c) in human blood samples. *Biosens. Bioelectron.* **2016**, *75*, 82-87.
- (12) Fägerstam, L. G.; Frostell-Karlsson, A.; Karlsson, R.; Persson, B.; Rönnberg, I. Biospecific interaction analysis using surface plasmon resonance detection applied to kinetic, binding site and concentration analysis. *J. Chromatogr.* **1992**, *597*, 397-410.
- (13) Karlsson, R. A.; Miachaelsson, A.; Matsson, L. Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. *J. Immunol. Methods* **1991**, *145*, 229-240.



(14) Walgama, C.; Al Mubarak, Z. H.; Zhang, B.; Akinwale, M.; Pathiranage, A.; Deng, J.; Berlin, K. D.; Benbrook, D. M.; Krishnan, S. Label-free real-time microarray imaging of cancer protein-protein interactions and their inhibition by small molecules. *Anal. Chem.* **2016**, *88*, 3130-3135.

(15) O'Shannessy, D. J.; Brigham-Burke, M.; Soneson, K. K.; Hensley, P.; Brooks, I. Determination of rate and equilibrium binding constants for macromolecular interactions using surface plasmon resonance: use of nonlinear least squares analysis methods. *Anal. Biochem.* **1993**, *212*, 457-468.